

Asia Pacific Biologics Market Forecast to 2031 - Regional Analysis - by Product (Monoclonal Antibodies, Vaccine, Recombinant Hormones/Proteins, Cell and Gene Therapy, and Others), Application (Cancer, Infectious Diseases, Autoimmune Diseases, and Others), Source (Mammalian and Microbial), and Manufacturing (Outsourced and In-house)

<https://marketpublishers.com/r/A71138DD2CF1EN.html>

Date: April 2025

Pages: 163

Price: US\$ 3,450.00 (Single User License)

ID: A71138DD2CF1EN

Abstracts

The Asia Pacific biologics market was valued at US\$ 1,01,590.5 million in 2023 and is expected to reach US\$ 4,17,082.9 million by 2031; it is estimated to register a CAGR of 19.3% from 2023 to 2031.

Evolution of Biotechnology in Developing Regions Fuels Asia Pacific Biologics Market

Antibodies are required in numerous applications in modern biotechnology, from fundamental research to innovative medical therapeutic approaches. The development of therapeutic antibodies has opened new avenues in treating various diseases, demonstrating the transformative ability of these particles. Antibodies are also crucial in diagnostics as they provide accurate and reliable approaches to disease identification. Growing support from governments, rising public-private partnerships, continuously changing disease profiles, and increasing funding activities are widely enhancing the performance of biotechnology industries in the regions such as Asia Pacific, South & Central America, and the Middle East & Africa. Countries such as the UAE, Saudi Arabia, Oman, Muscat, Bahrain, Taiwan, Malaysia, India, China, Singapore, and Japan are among the most lucrative markets for the biotechnology industry. Advancements in

biotechnology, genetics, and cell biology have contributed to the identification of several potential therapeutics for targeted treatments. Biotechnology is a strategic sector for China. The Made in China 2025 initiative emphasizes on research capabilities supporting the manufacturing of high-tech products, including innovative medicines. The plan introduced Chinese pharmaceutical companies to target areas to spur biotechnology innovation and enhance exports. Asian countries are more focused on using genomics, proteomics, and biomarker advancements for diagnostic and therapeutic applications. Therefore, the ongoing developments in the biotechnology industry in developing regions are expected to create opportunities for the biologics market in the coming years.

Asia Pacific Biologics Market Overview

The biologics market in Asia Pacific is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. The market growth in the region is driven by a large pool of patients living with genetic conditions and increasing investments in healthcare R&D by governments of respective countries. Over the past few years, there has been a significant rise in awareness about the benefits of biologics in China. Moreover, there was a rise in local access to a broad range of testing services for cell line characterization and many release from preclinical development to commercialization, creating a positive impact on the growth of the market. In recent years, scientists and health authorities have made efforts to highlight how biologics could be effectively utilized to study and treat diseases and develop pharmaceuticals and medical devices. They are also striving to strengthen their knowledge based on the mechanism of development of congenital disabilities. Samsung Biologics has signed a partnership agreement with China Biotech GeneQuantum Healthcare for the development of antibody-drug conjugate (ADC) for the treatment of non-small-cell lung carcinoma (NSCLC), triple-negative breast cancer (TNBC), and other solid tumors.

Asia Pacific Biologics Market Revenue and Forecast to 2031 (US\$ Million)

Asia Pacific Biologics Market Segmentation

The Asia Pacific biologics market is categorized into product, application, source, manufacturing, and country.

Based on product, the Asia Pacific biologics market is segmented into monoclonal antibodies, vaccine, recombinant hormones/proteins, cell and gene therapy, and others. The monoclonal antibodies segment held the largest market share in 2023.

In terms of application, the Asia Pacific biologics market is categorized into cancer, infectious diseases, autoimmune diseases, and others. The cancer segment held the largest market share in 2023.

By source, the Asia Pacific biologics market is bifurcated into mammalian and microbial. The mammalian segment held a larger market share in 2023.

Based on manufacturing, the Asia Pacific biologics market is bifurcated into outsourced and in-house. The outsourced segment held a larger market share in 2023.

In terms of country, the Asia Pacific biologics market is segmented into China, India, Japan, South Korea, Australia, and the Rest of Asia Pacific. China dominated the Asia Pacific biologics market share in 2023.

AbbVie Inc; Pfizer Inc; Samsung Biologics Co Ltd; ADMA Biologics, Inc.; Wuxi Biologics Inc; Catalent Inc; AGC Biologics AS; AstraZeneca Plc; Amgen Inc; Nitto Avecia; and Quality Assistance s.a. are some of the leading companies operating in the Asia Pacific biologics market.

Reason to buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific biologics market.

Highlights key business priorities to assist companies to realign their business strategies.

The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific biologics market, thereby allowing players across the value chain to develop effective long-term strategies.

Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.

Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the Asia Pacific biologics market, as well as those hindering it.

Enhance the decision-making process by understanding the strategies that

underpin commercial interest with respect to client products, segmentation, pricing, and distribution.

The List of Companies - Asia Pacific Biologics Market

AbbVie Inc

Pfizer Inc

Samsung Biologics Co Ltd

ADMA Biologics, Inc.

Wuxi Biologics Inc

Catalent Inc

AGC Biologics AS

AstraZeneca Plc

Amgen Inc

Nitto Avecia

Quality Assistance s.a.

Contents

1. INTRODUCTION

- 1.1 Report Guidance
- 1.2 Market Segmentation

2. EXECUTIVE SUMMARY

- 2.1 Key Insights
- 2.2 Market Attractiveness

3. RESEARCH METHODOLOGY

- 3.1 Secondary Research
- 3.2 Primary Research
 - 3.2.1 Hypothesis formulation:
 - 3.2.2 Macroeconomic factor analysis:
 - 3.2.3 Developing base number:
 - 3.2.4 Data Triangulation:
 - 3.2.5 Country-level data:

4. ASIA PACIFIC BIOLOGICS MARKET - KEY MARKET DYNAMICS

- 4.1 Market Drivers
 - 4.1.1 Increasing Prevalence of Chronic Diseases
 - 4.1.2 Preference for Outsourcing Manufacturing Operations
- 4.2 Market Restraints
 - 4.2.1 High Cost of Biologics
- 4.3 Market Opportunities
 - 4.3.1 Evolution of Biotechnology in Developing Regions
 - 4.3.2 Gene and Cell Therapy Advancements in Biologics
- 4.4 Future Trends
 - 4.4.1 Strategic Initiatives by Companies
- 4.5 Impact of Drivers and Restraints:

5. BIOLOGICS MARKET - ASIA PACIFIC ANALYSIS

- 5.1 Asia Pacific Biologics Market Revenue (US\$ Million), 2021-2031

5.2 Asia Pacific Biologics Market Forecast Analysis

6. ASIA PACIFIC BIOLOGICS MARKET ANALYSIS - BY PRODUCT

6.1 Monoclonal Antibodies

6.1.1 Overview

6.1.2 Monoclonal Antibodies: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million)

6.2 Vaccine

6.2.1 Overview

6.2.2 Vaccine: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million)

6.3 Recombinant Hormones/Proteins

6.3.1 Overview

6.3.2 Recombinant Hormones/Proteins: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million)

6.4 Cell and Gene Therapy

6.4.1 Overview

6.4.2 Cell and Gene Therapy: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million)

6.5 Others

6.5.1 Overview

6.5.2 Others: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million)

7. ASIA PACIFIC BIOLOGICS MARKET ANALYSIS - BY APPLICATION

7.1 Cancer

7.1.1 Overview

7.1.2 Cancer: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million)

7.2 Infectious Diseases

7.2.1 Overview

7.2.2 Infectious Diseases: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million)

7.3 Autoimmune Diseases

7.3.1 Overview

7.3.2 Autoimmune Diseases: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million)

7.4 Others

7.4.1 Overview

7.4.2 Others: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million)

8. ASIA PACIFIC BIOLOGICS MARKET ANALYSIS - BY SOURCE

8.1 Mammalian

8.1.1 Overview

8.1.2 Mammalian: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million)

8.2 Microbial

8.2.1 Overview

8.2.2 Microbial: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million)

9. ASIA PACIFIC BIOLOGICS MARKET ANALYSIS - BY MANUFACTURING

9.1 Outsourced

9.1.1 Overview

9.1.2 Outsourced: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million)

9.2 In-house

9.2.1 Overview

9.2.2 In-house: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million)

10. ASIA PACIFIC BIOLOGICS MARKET - COUNTRY ANALYSIS

10.1 Asia Pacific

10.1.1 Asia Pacific Biologics Market - Revenue and Forecast Analysis - by Country

10.1.1.1 Asia Pacific Biologics Market - Revenue and Forecast Analysis - by Country

10.1.1.2 China: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million)

10.1.1.2.1 China: Asia Pacific Biologics Market Share - by Product

10.1.1.2.2 China: Asia Pacific Biologics Market Share - by Application

10.1.1.2.3 China: Asia Pacific Biologics Market Share - by Source

10.1.1.2.4 China: Asia Pacific Biologics Market Share - by Manufacturing

10.1.1.3 India: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031

(US\$ Million)

10.1.1.3.1 India: Asia Pacific Biologics Market Share - by Product

10.1.1.3.2 India: Asia Pacific Biologics Market Share - by Application

10.1.1.3.3 India: Asia Pacific Biologics Market Share - by Source

10.1.1.3.4 India: Asia Pacific Biologics Market Share - by Manufacturing

10.1.1.4 Japan: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031

(US\$ Million)

10.1.1.4.1 Japan: Asia Pacific Biologics Market Share - by Product

10.1.1.4.2 Japan: Asia Pacific Biologics Market Share - by Application

10.1.1.4.3 Japan: Asia Pacific Biologics Market Share - by Source

10.1.1.4.4 Japan: Asia Pacific Biologics Market Share - by Manufacturing

10.1.1.5 South Korea: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million)

10.1.1.5.1 South Korea: Asia Pacific Biologics Market Share - by Product

10.1.1.5.2 South Korea: Asia Pacific Biologics Market Share - by Application

10.1.1.5.3 South Korea: Asia Pacific Biologics Market Share - by Source

10.1.1.5.4 South Korea: Asia Pacific Biologics Market Share - by Manufacturing

10.1.1.6 Australia: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million)

10.1.1.6.1 Australia: Asia Pacific Biologics Market Share - by Product

10.1.1.6.2 Australia: Asia Pacific Biologics Market Share - by Application

10.1.1.6.3 Australia: Asia Pacific Biologics Market Share - by Source

10.1.1.6.4 Australia: Asia Pacific Biologics Market Share - by Manufacturing

10.1.1.7 Rest of Asia Pacific: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million)

10.1.1.7.1 Rest of Asia Pacific: Asia Pacific Biologics Market Share - by Product

10.1.1.7.2 Rest of Asia Pacific: Asia Pacific Biologics Market Share - by Application

10.1.1.7.3 Rest of Asia Pacific: Asia Pacific Biologics Market Share - by Source

10.1.1.7.4 Rest of Asia Pacific: Asia Pacific Biologics Market Share - by Manufacturing

11. INDUSTRY LANDSCAPE

11.1 Overview

11.2 Market Initiative

11.3 Partnerships and Collaborations

11.4 Other Developments

12. COMPANY PROFILES

12.1 AbbVie Inc

- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments

12.2 Pfizer Inc

- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments

12.3 Samsung Biologics Co Ltd

- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments

12.4 ADMA Biologics, Inc.

- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments

12.5 WuXi Biologics Inc

- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments

12.6 Catalent Inc

- 12.6.1 Key Facts
- 12.6.2 Business Description

- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
- 12.7 AGC Biologics AS
 - 12.7.1 Key Facts
 - 12.7.2 Business Description
 - 12.7.3 Products and Services
 - 12.7.4 Financial Overview
 - 12.7.5 SWOT Analysis
 - 12.7.6 Key Developments
- 12.8 AstraZeneca Plc
 - 12.8.1 Key Facts
 - 12.8.2 Business Description
 - 12.8.3 Products and Services
 - 12.8.4 Financial Overview
 - 12.8.5 SWOT Analysis
 - 12.8.6 Key Developments
- 12.9 Amgen Inc
 - 12.9.1 Key Facts
 - 12.9.2 Business Description
 - 12.9.3 Products and Services
 - 12.9.4 Financial Overview
 - 12.9.5 SWOT Analysis
 - 12.9.6 Key Developments
- 12.10 Nitto AVECIA
 - 12.10.1 Key Facts
 - 12.10.2 Business Description
 - 12.10.3 Products and Services
 - 12.10.4 Financial Overview
 - 12.10.5 SWOT Analysis
 - 12.10.6 Key Developments
- 12.11 Quality Assistance s.a.
 - 12.11.1 Key Facts
 - 12.11.2 Business Description
 - 12.11.3 Products and Services
 - 12.11.4 Financial Overview
 - 12.11.5 SWOT Analysis
 - 12.11.6 Key Developments

13. APPENDIX

13.1 About Us

List Of Tables

LIST OF TABLES

- Table 1. Asia Pacific Biologics Market Segmentation
- Table 2. Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million)
- Table 3. Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million) - by Product
- Table 4. Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million) - by Application
- Table 5. Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million) - by Source
- Table 6. Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million) - by Manufacturing
- Table 7. Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million) - by Country
- Table 8. China: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Product
- Table 9. China: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Application
- Table 10. China: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Source
- Table 11. China: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Manufacturing
- Table 12. India: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Product
- Table 13. India: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Application
- Table 14. India: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Source
- Table 15. India: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Manufacturing
- Table 16. Japan: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Product
- Table 17. Japan: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Application
- Table 18. Japan: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Source

Table 19. Japan: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Manufacturing

Table 20. South Korea: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Product

Table 21. South Korea: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Application

Table 22. South Korea: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Source

Table 23. South Korea: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Manufacturing

Table 24. Australia: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Product

Table 25. Australia: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Application

Table 26. Australia: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Source

Table 27. Australia: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Manufacturing

Table 28. Rest of Asia Pacific: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Product

Table 29. Rest of Asia Pacific: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Application

Table 30. Rest of Asia Pacific: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Source

Table 31. Rest of Asia Pacific: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Manufacturing

List Of Figures

LIST OF FIGURES

Figure 1. Asia Pacific Biologics Market Segmentation - Country

Figure 2. Asia Pacific Biologics Market - Key Market Dynamics

Figure 3. Impact Analysis of Drivers and Restraints

Figure 4. Asia Pacific Biologics Market Revenue (US\$ Million), 2021-2031

Figure 5. Asia Pacific Biologics Market Share (%) - by Product (2023 and 2031)

Figure 6. Monoclonal Antibodies: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million)

Figure 7. Vaccine: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million)

Figure 8. Recombinant Hormones/Proteins: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million)

Figure 9. Cell and Gene Therapy: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million)

Figure 10. Others: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million)

Figure 11. Asia Pacific Biologics Market Share (%) - by Application (2023 and 2031)

Figure 12. Cancer: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million)

Figure 13. Infectious Diseases: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million)

Figure 14. Autoimmune Diseases: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million)

Figure 15. Others: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million)

Figure 16. Asia Pacific Biologics Market Share (%) - by Source (2023 and 2031)

Figure 17. Mammalian: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million)

Figure 18. Microbial: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million)

Figure 19. Asia Pacific Biologics Market Share (%) - by Manufacturing (2023 and 2031)

Figure 20. Outsourced: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million)

Figure 21. In-house: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US\$ Million)

Figure 22. Asia Pacific Biologics Market Breakdown, by Key Countries, 2023 and 2031

(%)

Figure 23. China: Asia Pacific Biologics Market - Revenue and Forecast, 2021- 2031 (US\$ Million)

Figure 24. India: Asia Pacific Biologics Market - Revenue and Forecast, 2021- 2031 (US\$ Million)

Figure 25. Japan: Asia Pacific Biologics Market - Revenue and Forecast, 2021- 2031 (US\$ Million)

Figure 26. South Korea: Asia Pacific Biologics Market - Revenue and Forecast, 2021- 2031 (US\$ Million)

Figure 27. Australia: Asia Pacific Biologics Market - Revenue and Forecast, 2021- 2031 (US\$ Million)

Figure 28. Rest of Asia Pacific: Asia Pacific Biologics Market - Revenue and Forecast, 2021- 2031 (US\$ Million)

I would like to order

Product name: Asia Pacific Biologics Market Forecast to 2031 - Regional Analysis - by Product (Monoclonal Antibodies, Vaccine, Recombinant Hormones/Proteins, Cell and Gene Therapy, and Others), Application (Cancer, Infectious Diseases, Autoimmune Diseases, and Others), Source (Mammalian and Microbial), and Manufacturing (Outsourced and In-house)

Product link: <https://marketpublishers.com/r/A71138DD2CF1EN.html>

Price: US\$ 3,450.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A71138DD2CF1EN.html>